Clinical Journal of Gastroenterology

, Volume 11, Issue 1, pp 48–52 | Cite as

Safe use of infliximab for the treatment of severe perianal Crohn’s disease after diagnosis and treatment of lymphoma

  • Carlos Bernardes
  • Pedro Russo
  • Diana Carvalho
  • Joana Saiote
  • Jaime Ramos
Case Report


Inflammatory bowel disease is associated with an increased likelihood of developing lymphoma. However, it is still controversial if this risk may be attributed to the disease itself or rather represents an effect of immunosuppressive treatment. Although tumor necrosis factor alpha (TNFα) is a key cytokine for cancer immunosurveillance, the potential relationship between anti-TNFα agents and the pathogenesis of lymphoproliferative disorders remains unclear. Here, we describe the case of a patient with severe perianal Crohn’s disease, treated with infliximab monotherapy, whose unusual presentation with acute groin pain required surgical intervention and led to the diagnosis of diffuse large B-cell lymphoma. However, 10 months after this episode, treatment with infliximab was restarted because the patient continued with refractory and disabling perianal disease. Currently, with a follow-up of 36 months, under infliximab 10 mg/kg every 4 weeks, he maintains mild perianal Crohn’s disease and persists in sustained clinical and imaging remission of the lymphoproliferative disorder.


Lymphoma Lymphoproliferative disorder Crohn’s disease Inflammatory bowel disease Infliximab Anti-TNFα 


Compliance with ethical standards

Conflict of interest

All authors declare no conflicts of interest.

Human rights

All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

Informed consent was obtained from all patients for being included in the study.


  1. 1.
    Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000;51:289–98.CrossRefPubMedGoogle Scholar
  2. 2.
    Kim DH, Cheon JH. Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies. Immune Netw. 2017;17(1):25–40.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Levin AD, Wildenberg ME, Gijs R, et al. Mechanism of action of anti-TNF therapy in inflammatory bowel disease. J Crohns Colitis. 2016;10(8):989–97.CrossRefPubMedGoogle Scholar
  4. 4.
    Wajant H. The role of TNF in cancer. Results Probl Cell Differ. 2009;49:1–15.CrossRefPubMedGoogle Scholar
  5. 5.
    Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15(Sup1):11–34.CrossRefPubMedGoogle Scholar
  6. 6.
    Lakatos PL, Miheller P. Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD? Curr Drug Targets. 2010;11(2):179–86.CrossRefPubMedGoogle Scholar
  7. 7.
    Jess T, Horváth-Puhó E, Fallingborg J, et al. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol. 2013;108(12):1869–76.CrossRefPubMedGoogle Scholar
  8. 8.
    Magro F, Peyrin-Biroulet L, Sokol H, et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohns Colitis. 2014;8(1):31–44.CrossRefPubMedGoogle Scholar
  9. 9.
    Bichile T, Petri M. Incidence of lymphoma associated with underlying lupus: lessons learned from observational studies. Curr Opin Rheumatol. 2014;26(2):111–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Bernatsky S, Boivin J-F, Joseph L, et al. An international cohort study of cancer in SLE. Arthritis Rheum. 2005;52(5):1481–90.CrossRefPubMedGoogle Scholar
  11. 11.
    Ekström K, Hjalgrim H, Brandt L, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first degree relatives. Arthritis Rheum. 2003;48(4):963–70.CrossRefPubMedGoogle Scholar
  12. 12.
    Sokol H, Laurent B. Lymphoma risks in IBD. In: Bayless TM, Hanauer S, editors. Advanced therapy in inflammatory bowel disease. volume I: IBD and ulcerative colitis. 3rd ed. Shelton: People’s Medical Publishing House; 2011. p. 489–97.Google Scholar
  13. 13.
    Chiorean MV, Pokhrel B, Adabala J, et al. Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population. Dig Dis Sci. 2011;56(5):1489–95.CrossRefPubMedGoogle Scholar
  14. 14.
    Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001;121(5):1080–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Pedersen N, Duricova D, Elkjaer M, et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol. 2010;105(7):1480–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Beaugerie L, Brousse N, Bouvier AM, CESAME Study Group, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–25.CrossRefPubMedGoogle Scholar
  17. 17.
    Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013;145(5):1007–15.CrossRefPubMedGoogle Scholar
  18. 18.
    Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70(11):1895–904.CrossRefPubMedGoogle Scholar
  19. 19.
    Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012;107(9):1409–22.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Menon MP, Pittaluga S, Jaffe ES. The histological and biological spectrum of diffuse large B-cell lymphoma in the WHO classification. Cancer J. 2012;18(5):411–20.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Møller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation − a population-based study of 1575 cases. Br J Haematol. 2004;124(2):151–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Flynn AD, Azar JM, Chiorean MV. Spontaneous regression of colonic lymphoma following infliximab and azathioprine withdrawal in patients with Crohn’s disease. Inflamm Bowel Dis. 2013;19(5):E69–70.CrossRefPubMedGoogle Scholar
  23. 23.
    Khanna M, Buddhavarapu SR. Primary Burkitt’s lymphoma of the appendix presenting as acute abdomen: a case report. J Radiol Case Rep. 2008;2(5):9–14.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Boscà-Robledo A, Pous-Serrano S, García-Mayor RL, et al. Acute abdomen as the first manifestation of a post-transplant lymphoproliferative disorder. Int J Colorectal Dis. 2011;26(8):1081–2.CrossRefPubMedGoogle Scholar
  25. 25.
    Negrean V, Graur F, Moiş E, et al. Ileocecal obstruction due to B-cell non-Hodgkin lymphoma. Chirurgia (Bucur). 2016;111(1):71–3.Google Scholar
  26. 26.
    Ishii W, Ito S, Kondo Y, et al. Intravascular large B-cell lymphoma with acute abdomen as a presenting symptom in a patient with systemic lupus erythematosus. J Clin Oncol. 2008;26(9):1553–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Flynn AD, Azar JM, Chiorean MV. Spontaneous regression of colonic lymphoma following infliximab and azathioprine withdrawal in patients with Crohn’s disease. Inflamm Bowel Dis. 2013;19(5):E69–70.CrossRefPubMedGoogle Scholar
  28. 28.
    Cassaday RD, Malik JT, Chang JE. Regression of Hodgkin lymphoma after discontinuation of a tumor necrosis factor inhibitor for Crohn’s disease: a case report and review of the literature. Clin Lymphoma Myeloma Leuk. 2011;11(3):289–92.CrossRefPubMedGoogle Scholar
  29. 29.
    Mo N, Murthu S, O’Sullivan M. Regression of lymphoma after withdrawal of infliximab alone in an infliximab/methotrexate-treated RA patient. Rheumatology. 2011;50(4):808–10.CrossRefPubMedGoogle Scholar
  30. 30.
    Thonhofer R, Gaugg M, Kriessmayr M, et al. Spontaneous remission of marginal zone B cell lymphoma in a patient with seropositive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment. Ann Rheum Dis. 2005;64(7):1098–9.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Komatsuda A, Wakui H, Nimura T, et al. Reversible infliximab-related lymphoproliferative disorder associated with Epstein–Barr virus in a patient with rheumatoid arthritis. Mod Rheumatol. 2008;18(3):315–8.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2017

Authors and Affiliations

  1. 1.Gastroenterology DepartmentCentro Hospitalar de Lisboa CentralLisbonPortugal
  2. 2.BarcarenaPortugal

Personalised recommendations